Brief: Ascentage Pharma Group International Announces CDE's Approval For Phase II Study Of Lisaftoclax
13/12/2021 01:09
Dec 13 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ANNOUNCES CDE'S APPROVAL FOR PHASE II PIVOTAL STUDY IN
CHINA OF
BCL-2 INHIBITOR LISAFTOCLAX
Source text for Eikon: urn:newsml:reuters.com:*:nHKS9YkyCS
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up